Obsidio is a medical device company pioneering a biomaterial platform technology to enable minimally-invasive occlusion of blood vessels.
Obsidio, Inc. is an early-stage medical device company pioneering a biomaterial platform technology to enable minimally-invasive occlusion of blood vessels anywhere in the body regardless of the patient’s coagulopathy. The technology can be used to control bleeding, close off vessels supplying blood to tumor, eliminate abnormal connections between arteries and veins, and treat aneurysms.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Aug 6, 2020 | Grant | $225K | 1 | National Science Foundation | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
National Science Foundation | Yes | Grant |